Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: A meta-analysis and systematic review

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 1, 2014, Pages 32-44.e5

  Melek, John ^a,b   Sakuraba, Atsushi ^c  

^a MERCY HOSPITAL AND MEDICAL CENTER   (United States)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

CD; Clinical Trial; Estrogen; Osteopenia; UC

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; DENOSUMAB; ESTROGEN DERIVATIVE; ETIDRONIC ACID; FLUORIDE SODIUM; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID GLAND HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ABDOMINAL PAIN; AEROBIC EXERCISE; BONE DENSITY; CLINICAL EVALUATION; COCHRANE LIBRARY; COLITIS; CROHN DISEASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EMBASE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; INDETERMINATE COLITIS; LUMBAR SPINE; MEDICAL INFORMATION SYSTEM; MEDLINE; META ANALYSIS; NAUSEA; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; SPINE FRACTURE; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; COMPLICATION; CONTROLLED CLINICAL TRIAL (TOPIC); FRACTURES, BONE; INFLAMMATORY BOWEL DISEASE; TREATMENT OUTCOME;

BONE DENSITY CONSERVATION AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; INFLAMMATORY BOWEL DISEASES; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 84890209884     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.08.024     Document Type: Review

References (58)

1. Dinca M., Fries W., Luisetto G., et al. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 1999, 94:1292-1297.
2. Motley R.J., Clements D., Evans W.D., et al. Afour-year longitudinal study of bone loss in patients with inflammatory bowel disease. Bone Miner 1993, 23:95-104.
3. Silvennoinen J.A., Karttunen T.J., Niemela S.E., et al. Acontrolled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995, 37:71-76.
4. Bernstein C.N., Blanchard J.F., Leslie W., et al. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med 2000, 133:795-799.
5. van Staa T.P., Cooper C., Brusse L.S., et al. Inflammatory bowel disease and the risk of fracture. Gastroenterology 2003, 125:1591-1597.
6. Bernstein C.N., Leslie W.D., Leboff M.S. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003, 124:795-841.
7. Lewis N., Scott B. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. British Society of Gastroenterology 2007, 14:1-16.
8. Abitbol V., Roux C., Chaussade S., et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995, 108:417-422.
9. Klaus J., Armbrecht G., Steinkamp M., et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002, 51:654-658.
10. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
11. Russell R.G., Rogers M.J., Frith J.C., et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. JBone Miner Res 1999, 14(Suppl 2):53-65.
12. Bernstein C.N., Seeger L.L., Anton P.A., et al. Arandomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996, 10:777-786.
13. Kitazaki S., Mitsuyama K., Masuda J., et al. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. Aliment Pharmacol Ther 2009, 29:424-430.
14. Klaus J., Haenle M.M., Schroter C., et al. Asingle dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial. Am J Gastroenterol 2011, 106:786-793.
15. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
16. Thompson S.G., Higgins J.P. How should meta-regression analyses be undertaken and interpreted?. Stat Med 2002, 21:1559-1573.
17. Pigott T. Advances in meta-analysis 2012, Springer, New York.
18. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
19. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
20. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration,2011.
21. Benchimol E.I., Ward L.M., Gallagher J.C., et al. Effect of calcium and vitamin D supplementation on bone mineral density in children with inflammatory bowel disease. JPediatr Gastroenterol Nutr 2007, 45:538-545.
22. Haderslev K.V., Tjellesen L., Sorensen H.A., et al. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000, 119:639-646.
23. Bartram S.A., Peaston R.T., Rawlings D.J., et al. Arandomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003, 18:1121-1127.
24. von Tirpitz C., Klaus J., Steinkamp M., et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003, 17:807-816.
25. Palomba S., Orio F., Manguso F., et al. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 2005, 16:1141-1149.
26. Siffledeen J.S., Fedorak R.N., Siminoski K., et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2005, 3:122-132.
27. Henderson S., Hoffman N., Prince R. Adouble-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006, 101:119-123.
28. Abitbol V., Briot K., Roux C., et al. Adouble-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5:1184-1189.
29. Kriel M.H., Tobias J.H., Creed T.J., et al. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease. Osteoporos Int 2010, 21:507-513.
30. Sbrocchi A.M., Forget S., Laforte D., et al. Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease. Pediatr Int 2010, 52:754-761.
31. Klaus J., Reinshagen M., Herdt K., et al. Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. World J Gastroenterol 2011, 17:334-342.
32. Klaus J., Reinshagen M., Herdt K., et al. Intravenous ibandronate or sodium-fluoride: a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis. JGastrointest Liver Dis 2011, 20:141-148.
33. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. NEngl J Med 2001, 344:333-340.
34. Abitbol V., Mary J.Y., Roux C., et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 2002, 16:919-927.
35. von Tirpitz C., Klaus J., Bruckel J., et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000, 12:19-24.
36. Haguenauer D., Welch V., Shea B., et al. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 2000, 11:727-738.
37. Pappa H.M., Saslowsky T.M., Filip-Dhima R., et al. Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: a randomized, placebo-controlled, double-blind trial. Am J Gastroenterol 2011, 106. 1527-1543.
38. Robinson R.J., Krzywicki T., Almond L., et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998, 115:36-41.
39. Shea B., Wells G., Cranney A., et al. Meta-analyses of therapies for postmenopausal osteoporosis: VII-meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002, 23:552-559.
40. Papadimitropoulos E., Wells G., Shea B., et al. Meta-analyses of therapies for postmenopausal osteoporosis: VIII-meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002, 23:560-569.
41. Gillespie W.J., Avenell A., Henry D.A., et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2001, CD000227.
42. Cranney A., Adachi J.D. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf 2005, 28:721-730.
43. Le Pen C., Maurel F., Breart G., et al. The long-term effectiveness of preventive strategies for osteoporosis in postmenopausal women: a modeling approach. Osteoporos Int 2000, 11:524-532.
44. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. NEngl J Med 1997, 337:382-387.
45. Adachi J.D. Corticosteroid-induced osteoporosis. Am J Med Sci 1997, 313:41-49.
46. Ensrud K.E., Black D.M., Palermo L., et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997, 157:2617-2624.
47. Clements D., Compston J.E., Evans W.D., et al. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993, 34:1543-1546.
48. Canonico M., Plu-Bureau G., Lowe G.D., et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008, 336:1227-1231.
49. Pak C.Y., Sakhaee K., Adams-Huet B., et al. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med 1995, 123:401-408.
50. Rubin C.D., Pak C.Y., Adams-Huet B., et al. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med 2001, 161:2325-2333.
51. Chesnut C.H., Silverman S., Andriano K., et al. Arandomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study-PROOF Study Group. Am J Med 2000, 109:267-276.
52. Cranney A., Welch V., Adachi J.D., et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000, CD001983.
53. Cranney A., Tugwell P., Zytaruk N., et al. Meta-analyses of therapies for postmenopausal osteoporosis: VI-meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002, 23:540-551.
54. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEngl J Med 2001, 344:1434-1441.
55. Montemurro L., Schiraldi G., Fraioli P., et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991, 49:71-76.
56. Sambrook P., Birmingham J., Kelly P., et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. NEngl J Med 1993, 328:1747-1752.
57. Chung M., Lee J., Terasawa T., et al. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 155:827-838.
58. Rachner T.D., Khosla S., Hofbauer L.C. Osteoporosis: now and the future. Lancet 2011, 377:1276-1287.